Full history for every metric is available with a Kvantra account
Albireo Pharma, Inc. (ALBO)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 11 | 0 | 13 | 10 | 8 | 41 | 57 |
| Operating profit | $m | -123 | -123 | |||||
| Net profit | $m | -16 | -24 | -46 | -72 | -119 | -151 | -137 |
| EPS reported | $ | -7.87 | -7.04 | |||||
| Operating cashflow per share | $ | -5.60 | -5.60 | |||||
| Capex per share | $ | 0.02 | 0.02 | |||||
| FCF per share | $ | -5.62 | -5.62 | |||||
| Free cash flow | $m | -108 | -117 | |||||
| Net debt | $m | -238 | -222 | |||||
| Book value equity | $m | 176 | 100 | |||||
| Book value per share | $ | 9.14 | 5.09 | |||||
| Number of shares | m | 19.22 | 19.66 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.55 | 9.15 | |||||
| P/S LTM | x | 11.03 | 15.96 | |||||
| P/FCF LTM | x | -4.14 | -7.86 | |||||
| EV/EBITDA LTM | x | -10.57 | -6.71 | |||||
| EV/Sales LTM | x | 5.16 | 12.08 | |||||
| Earnings Yield LTM | % | -33.81% | -17.83% | |||||
| FCF Yield | % | -24.13% | -12.73% | |||||
| Quality | ||||||||
| ROE | % | -86.19% | -84.83% | |||||
| ROIC | % | -48.10% | -48.10% | |||||
| Operating margin | % | -304.31% | -304.31% | |||||
| Gross margin | % | 96.66% | 96.66% | |||||
| FCF/Sales | % | -266.21% | -266.21% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +388.43% | +432.68% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -10.80 | - | |||||
| Net Debt/EBITDA | x | 12.01 | 12.01 | |||||
| EBIT/Net interest | x | -8.86 | -8.86 | |||||
| Net debt/market cap | % | -53.19% | -24.29% | |||||
| Net debt/Equity | x | -1.36 | -2.22 | |||||
| Gross debt/equity | x | 0.06 | 0.00 | |||||
Company overview
Albireo Pharma, Inc. is a biopharmaceutical company with marketed products, dedicated to researching, developing, and commercializing new treatments that modify bile acids. The company primarily targets rare liver diseases in children, as well as various other conditions affecting the liver or digestive system. Its portfolio includes Bylvay, a treatment approved for progressive familial intrahepatic cholestasis. Bylvay is also in advanced (Phase III) clinical trials for further pediatric indications such as biliary atresia and Alagille syndrome, which are both uncommon and serious childhood disorders. Additionally, Albireo offers Elobixibat, prescribed for the management of persistent constipation and other functional gastrointestinal issues. Albireo is further advancing its pipeline with A3907, currently undergoing early-stage (Phase I) clinical investigation for adult liver diseases, and A2342, a preclinical candidate designed to address adult viral and liver conditions. The company holds a licensing agreement with EA Pharma Co., Ltd. concerning the development and market rollout of Elobixibat. Albireo Pharma, Inc.'s headquarters are located in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Albireo Pharma, Inc. (ALBO)
Albireo Pharma, Inc. is a biopharmaceutical company with marketed products, dedicated to researching, developing, and commercializing new treatments that modify bile acids. The company primarily targets rare liver diseases in children, as well as various other conditions affecting the liver or digestive system. Its portfolio includes Bylvay, a treatment approved for progressive familial intrahepatic cholestasis. Bylvay is also in advanced (Phase III) clinical trials for further pediatric indications such as biliary atresia and Alagille syndrome, which are both uncommon and serious childhood disorders. Additionally, Albireo offers Elobixibat, prescribed for the management of persistent constipation and other functional gastrointestinal issues. Albireo is further advancing its pipeline with A3907, currently undergoing early-stage (Phase I) clinical investigation for adult liver diseases, and A2342, a preclinical candidate designed to address adult viral and liver conditions. The company holds a licensing agreement with EA Pharma Co., Ltd. concerning the development and market rollout of Elobixibat. Albireo Pharma, Inc.'s headquarters are located in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free